This company has been acquired
Abiomed Balance Sheet Health
Financial Health criteria checks 6/6
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -62.2x |
| Cash | US$820.37m |
| Equity | US$1.54b |
| Total liabilities | US$156.76m |
| Total assets | US$1.70b |
Recent financial health updates
No updates
Recent updates
Abiomed's Impella low profile sheath gets FDA clearance
Oct 17Abiomed: Correction Offers Good Buying Opportunity
Sep 28U.S. FDA gives two approvals to Abiomed Impella heart pumps
Sep 16Abiomed FQ1 2023 Earnings Preview
Aug 03Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages
May 17Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk
Jan 24Abiomed: Impella Will Continue To Drive Revenue Growth
Sep 10Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating
Jul 13DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue
Jun 08Abiomed acquires preCARDIA a company targeting acute heart failure
Jun 01Boston Scientific’s new clinical trial can impact Abiomed: Raymond James
May 06Abiomed FQ4 2021 Earnings Preview
Apr 28Financial Position Analysis
Short Term Liabilities: ABMD's short term assets ($1.1B) exceed its short term liabilities ($134.1M).
Long Term Liabilities: ABMD's short term assets ($1.1B) exceed its long term liabilities ($22.7M).
Debt to Equity History and Analysis
Debt Level: ABMD is debt free.
Reducing Debt: ABMD had no debt 5 years ago.
Debt Coverage: ABMD has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ABMD has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/12/24 05:40 |
| End of Day Share Price | 2022/12/21 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abiomed, Inc. is covered by 26 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lawrence Neibor | Baird |
| Jan Wald | Benchmark Company |
| Michael Gorman | BTIG |